Qudexy XR for Pediatric Migraine Prevention

"Qudexy XR is a traditional treatment for hypertension. Other potential uses of this medication include prophylaxis against migraine headaches, epilepsy, and at least one obesity-related comorbidity."

"This clinical trial has 11 distinct enrolment sites, including Upsher-Smith Clinical Trial Site #9 in Mobile, Upsher-Smith Clinical Trial Site #5 in Birmingham, and Upsher-Smith Clinical Trial Site#1 in Stamford. 8 other locations are also hosting this study."

"The safety of Qudexy XR is rated 3 out of 3, as this medication has already been approved for use in Phase 4 clinical trials."

"Affirmative. The listing of this clinical trial on the website for clinicaltrials.gov confirms that it is actively recruiting, with 132 patients needed from 11 different sites. It was first posted in February 2021 and most recently updated at the end of April 2022."

"Originally studied in 2013 at UC Davis Medical Center, Qudexy XR has since been the subject of 18417 clinical trials. At present, 18 separate research projects are ongoing, with many based out of Mobile, Alabama."

"This clinical trial has room for 132 children between the ages of six and eleven who have been diagnosed with sick headache. Additional inclusion criteria are that participants must possess a minimum 6-month history of headaches which aligns to ICHD 3, weigh no less than 17kg and up 50 kg based on 95 percentile weight for their age, record 8 or more self-reported headache days in the month prior to screening, and present a PedMIDAS score greater than 10 but lower than 140."

"This clinical trial has established an age range of 6-11 as the required parameters for patient participation."

"Affirmative, per the clinicaltrials.gov entry for this trial, enrollment is currently open to candidates. The protocol was published on February 19th 2021 and has since been revised on April 26th 2022. 132 participants across 11 sites are being sought out for inclusion in the study."